Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination

References

• American Diabetes AssociationStandards of Medical Care in DiabetesDiabetes Care200629S44216373931
   PubMed Web of Science ®Google Scholar
• BaksiAJamesREZhouBComparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylureaActa Diabetol20044163915224207
   PubMed Web of Science ®Google Scholar
• DebrilMBRenaudJPFajasLThe pleiotropic functions of peroxisome proliferator-activated receptor γJ Mol Med200279304711327101
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAVMetabolic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and metabolic syndrome treated with glimepiride: a twelve month, multicenter, randomized, controlled, parallel group trialClin Ther2004267445415220018
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAVA comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on pro-thrombotic state in type 2 diabetic patients with the metabolic syndromeDiabetes Res Clin Pract2005a6951315955382
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAVLong-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12 month, double-blind, randomized clinical trialClin Ther2005b2713839116291411
   PubMed Web of Science ®Google Scholar
• DerosaGGaddiAVPiccinniMNDifferential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trialDiabetes Obes Metab2006819720516448524
   PubMed Web of Science ®Google Scholar
• FukuenSIwakiMYasuiASulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activityJ Biol Chem200528023653915764598
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline2006 URL: http://US.gsk.com/product/assets/us_fixedcombinationofglimepirideandrosiglitazone.pdf
   Google Scholar
• HaffnerSMGreenbergASWestonWMEffect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitusCirculation20021066798412163427
   PubMed Web of Science ®Google Scholar
• HallstenJKVirtanenKALonnqvistFRosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetesDiabetes20025134798512453903
   PubMed Web of Science ®Google Scholar
• HamannAMatthaeiSMauersbergerHEfficacy and Safety of Rosiglitazone in Combination with GlimepirideDiabetes Metab200329Suppl 22288
   Google Scholar
• HermanWHDiraniRGHorblyukRReduction in use of health-care services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) studyAm J Manag Care200511273815839187
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med200635524274317145742
   PubMed Web of Science ®Google Scholar
• KerenyiZSamerHJamesRCombination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients wit type 2 diabetes mellitusDiabetes Res Clin Pract2004632132314757293
   PubMed Web of Science ®Google Scholar
• KerstenSDesvergneBWahliWRoles of PPARs in health and diseaseNature2000405421410839530
   PubMed Web of Science ®Google Scholar
• LangtryHDBalfourJAGlimiperide. A Review of its use in the management of type 2 diabetes mellitusDrugs199855563849561345
   PubMed Web of Science ®Google Scholar
• MarxNFroehlichJSiamLAntidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery diseaseArterioscler Thromb Vasc Biol2003a23283812588772
   PubMed Web of Science ®Google Scholar
• MarxNImhofAFroehlichJEffect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery diseaseCirculation2003b1071954712695287
   PubMed Web of Science ®Google Scholar
• McCallALClinical review of glimepirideExpert Opin Pharmacother2001269971311336617
   PubMedGoogle Scholar
• McCluskeyDTougerMSMelisRResults of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapyClin Ther20042617839015639690
   PubMed Web of Science ®Google Scholar
• MohantyPAljadaAGhanimHEvidence for a potent antiinflammatory effect of rosiglitazoneJ Clin Endocrinol Metab20048927283515181049
   PubMed Web of Science ®Google Scholar
• NataliABaldewegSToschiEVascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetesDiabetes Care20042713495715161787
   PubMed Web of Science ®Google Scholar
• OrbayESarginMSarginHAddition of rosiglitazone to glimepiride and metformin combination therapy in type 2 diabetesEndocr J200451521715644569
   PubMed Web of Science ®Google Scholar
• PfütznerAKannPPfütznerAHIntact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetesClin Lab2004505677315481632
   PubMedGoogle Scholar
• PfütznerASchöndorfTSeidelDImpact of rosiglitazone on β-cell function, insulin resistance and adiponektin concentrations— Results from a double blind oral combination study with glimepirideMetabolism2006a55205
   PubMed Web of Science ®Google Scholar
• PfütznerAPanskyAMaiwormAMesenchymal stem cell differentiation into adipocytes is equally induced by insulin and proinsulin in vitroDiabetologia2006b49Suppl 1P707
   Google Scholar
• PickupJWilliamsGTextbook of Diabetes20023rd edOxfordBlackwell Publishing
   Google Scholar
• RobertsVLStewartJIssaMTriple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results from a 30-week, randomized, double-blind, placebo-controlled, parallel-group studyClin Ther20052715354716330290
   PubMed Web of Science ®Google Scholar
• RosenstockJGoldsteinBJVinikAIEffect of early addition of rosiglitazone to sulphonylurea therapy in older patients with type 2 diabetes (>60 years): the Rosiglitazone Early vs SULfonylurea Titration (RESULT) studyDiabetes Obes Metab20058495716367882
   PubMed Web of Science ®Google Scholar
• RosenstockJSugimotoDStrangePTriple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patientsDiabetes Care2006a29554916505505
   PubMed Web of Science ®Google Scholar
• RosenstockJFerreira-CornwellCWestonWMRosiglitazone added early to glimepiride provides superior glycaemic control than uptitration of glimepiride alone in type 2 diabetes (T2DM)Diabetes2006b55Suppl,1P549
   Google Scholar
• SchneiderDJNordtTKSobelBEStimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cellsDiabetes19924189051612205
   PubMed Web of Science ®Google Scholar
• SchoonjansKAuwerxJThiazolidinediones: an updateLancet200035510081010768450
   PubMed Web of Science ®Google Scholar
• ShargorodskyMWainsteinJGavishDTreatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitusAm J Hypertens2002166172212878365
   PubMed Web of Science ®Google Scholar
• TiikkainenMHakkinenAMKorsheninnikovaEEffects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetesDiabetes20045321697615277403
   PubMed Web of Science ®Google Scholar
• UebaHKurokiMHashimotoSGlimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathwayAtherosclerosis200518335916216590
   PubMed Web of Science ®Google Scholar
• VongthavaravatVWajchenbergBLWaitmanJNAn international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetesCurr Med Res Opin2002184566112564655
   PubMed Web of Science ®Google Scholar
• WagstaffAJGoaKLRosiglitazone: a review of its use in the management of type 2 diabetes mellitusDrugs20026218053712149047
   PubMed Web of Science ®Google Scholar
• WellingtonKRosiglitazone/MetforminDrugs20056515819216033298
   PubMed Web of Science ®Google Scholar
• WolffenbüttelBHGomisRSquatritoSAddition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patientsDiab Med200017407
   PubMed Web of Science ®Google Scholar
• YangJDiFHeREfffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycaemic control in type 2 diabetic patientsChin Med J (Engl)2003116785712875702
   PubMed Web of Science ®Google Scholar
• ZhuXXPanCYLiGWAddition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or CDiabetes Technol Ther20035334212725705
   PubMedGoogle Scholar
• ZimmetPAlbertiKGShawJGlobal and societal implications of the diabetes epidemicNature2001407782711742409
   PubMedGoogle Scholar